Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction

This publication has 15 references indexed in Scilit:

• Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction
  Circulation, 2003
• Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE) *
  Published by Elsevier ,2002
• Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction. Insights from TIMI 14 and InTIME-II
  European Heart Journal, 2002
• Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction
  Circulation, 2002
• Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin
  Circulation, 2001
• Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
  New England Journal of Medicine, 2001
• Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
  The Lancet, 2001
• Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14
  European Heart Journal, 2000
• Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction
  Circulation, 2000
• Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
  Circulation, 1993